Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adult patients. GNH USA supplies Moxifloxacin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin Krka is a fluoroquinolone used for infections caused by susceptible bacteria. - Community‑acquired pneumonia: improves clinical cure rates by targeting typical and atypical pathogens. - Acute bacterial sinusitis: reduces symptom duration and bacterial load. - Complicated skin and skin‑structure infections: provides bactericidal activity against Gram‑negative and Gram‑positive organisms. - Intra‑abdominal infections: effective against mixed aerobic and anaerobic flora when used intravenously. - Acute bacterial exacerbation of chronic bronchitis: shortens recovery time and limits disease progression.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: often self‑limiting watery stools. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensations. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile infection: severe colitis following gut flora disruption. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but potentially life‑threatening liver injury. - Peripheral neuropathy: persistent sensory deficits.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function assessment: adjust therapy in severe impairment. - QT interval monitoring: avoid in patients with known prolongation or concurrent QT‑prolonging drugs. - Tendon disorder avoidance: do not use in patients with a history of tendon disease. - Hepatic impairment caution: monitor liver enzymes during treatment. - Concomitant medication review: assess for drugs that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increase risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce oral absorption (not applicable to IV but caution with concurrent oral forms). - Warfarin: may potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of CNS stimulation and seizures. - Corticosteroids: additive risk of tendon rupture. - Cyclosporine: possible increase in moxifloxacin plasma concentrations.